DK1569680T3 - Behandling af diabetes - Google Patents
Behandling af diabetesInfo
- Publication number
- DK1569680T3 DK1569680T3 DK03774936T DK03774936T DK1569680T3 DK 1569680 T3 DK1569680 T3 DK 1569680T3 DK 03774936 T DK03774936 T DK 03774936T DK 03774936 T DK03774936 T DK 03774936T DK 1569680 T3 DK1569680 T3 DK 1569680T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- diabetes
- treatment
- gastin
- complement
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3695—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42039902P | 2002-10-22 | 2002-10-22 | |
US42018702P | 2002-10-22 | 2002-10-22 | |
US42810002P | 2002-11-21 | 2002-11-21 | |
US42856202P | 2002-11-22 | 2002-11-22 | |
PCT/US2003/033595 WO2004037195A2 (fr) | 2002-10-22 | 2003-10-22 | Traitement du diabete |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1569680T3 true DK1569680T3 (da) | 2009-05-18 |
Family
ID=32180693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03774936T DK1569680T3 (da) | 2002-10-22 | 2003-10-22 | Behandling af diabetes |
Country Status (15)
Country | Link |
---|---|
US (3) | US20060189520A1 (fr) |
EP (2) | EP2080521A1 (fr) |
JP (1) | JP2006506386A (fr) |
KR (1) | KR20050074492A (fr) |
AT (1) | ATE421333T1 (fr) |
AU (1) | AU2003283004A1 (fr) |
BR (1) | BR0315523A (fr) |
CA (1) | CA2501677A1 (fr) |
DE (1) | DE60326002D1 (fr) |
DK (1) | DK1569680T3 (fr) |
ES (1) | ES2320754T3 (fr) |
MX (1) | MXPA05004202A (fr) |
NO (1) | NO20052419L (fr) |
PL (1) | PL376473A1 (fr) |
WO (1) | WO2004037195A2 (fr) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US6992060B2 (en) | 2001-01-12 | 2006-01-31 | Waratah Pharmaceuticals, Inc. | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
CA2494134A1 (fr) * | 2002-05-24 | 2003-12-04 | Waratah Pharmaceuticals, Inc. | Traitement du diabete |
DE60329724D1 (de) | 2002-06-07 | 2009-11-26 | Waratah Pharmaceuticals Inc | Methoden und Kompositionen um Diabetes zu behandeln |
EP1837031B1 (fr) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methodes et compositions pour le traitement du diabete |
AU2003283004A1 (en) * | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
ES2737835T3 (es) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Bomba accionada hidráulicamente para la administración de medicamentos de larga duración |
US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
CN1829528A (zh) * | 2003-05-27 | 2006-09-06 | 瓦拉塔药品公司 | 包含胃泌素化合物的组合物及其在糖尿病中的应用 |
JP2007512102A (ja) | 2003-11-20 | 2007-05-17 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン, インク. | 流体の吸引のための携帯可能な手動ポンプ |
JP2007519642A (ja) * | 2004-01-30 | 2007-07-19 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 血糖値を調節するためのglp−1アゴニストとガストリンとの合わせた使用 |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
WO2006000567A2 (fr) * | 2004-06-28 | 2006-01-05 | Novo Nordisk A/S | Methodes de traitement du diabete |
WO2006002532A1 (fr) * | 2004-07-01 | 2006-01-12 | Waratah Pharmaceuticals, Inc. | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete |
WO2006014425A1 (fr) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Procedes et dispositifs pour l'administration du glp-1 et leurs utilisations |
US8361976B2 (en) * | 2004-07-09 | 2013-01-29 | University Of Massachusetts | Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules |
US8337475B2 (en) | 2004-10-12 | 2012-12-25 | C. R. Bard, Inc. | Corporeal drainage system |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (fr) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solutions de solvant/polymere utilisees comme vehicules de suspension |
EP2390264A1 (fr) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US20070031373A1 (en) * | 2005-08-04 | 2007-02-08 | Carlos Lopez | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors |
WO2007038643A1 (fr) | 2005-09-26 | 2007-04-05 | C.R. Bard, Inc. | Systèmes de raccord de cathéther |
CN101365476A (zh) * | 2005-10-07 | 2009-02-11 | 瓦拉塔药品公司 | Dpp-iv抑制剂和胃泌素化合物的联合使用 |
US20070100322A1 (en) * | 2005-10-31 | 2007-05-03 | Ramakrishna Venugopalan | Method of removing a stylette from a catheter |
US20090162345A1 (en) * | 2005-11-29 | 2009-06-25 | Atkinson Mark A | Materials and Methods for Reversing Type-1 Diabetes |
WO2007095737A1 (fr) * | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Polythérapie pour le traitement du diabète, comprenant un agoniste d'exendine et un composé de gastrine |
JP2009527504A (ja) * | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
JP2009532117A (ja) | 2006-03-30 | 2009-09-10 | ヴァレリタス,エルエルシー | マルチカートリッジ式流体投与装置 |
DE602007009377D1 (de) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
AU2008244523B2 (en) | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
WO2009023566A2 (fr) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Procédé de traitement d'une maladie auto-immune avec des cellules souches mésenchymateuses |
WO2009046015A2 (fr) * | 2007-09-30 | 2009-04-09 | University Of Florida Research Foundation, Inc. | Thérapies combinées pour traitement de diabète du type 1 |
EP2240155B1 (fr) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
US8512737B1 (en) * | 2008-06-03 | 2013-08-20 | Abbott Cardiovascular Systems Inc. | Embolic delivery of therapeutic agents |
CN102170895A (zh) | 2008-08-07 | 2011-08-31 | 益普生制药股份有限公司 | 葡萄糖依赖性促胰岛素多肽类似物 |
AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
KR101419583B1 (ko) * | 2008-10-15 | 2014-07-25 | 인타르시아 세라퓨틱스 인코포레이티드 | 고농축 약물 입자, 제형, 현탁액 및 이들의 용도 |
US8821872B2 (en) * | 2009-05-01 | 2014-09-02 | Jill P. Smith | Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer |
US8383671B1 (en) | 2009-06-18 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Method of treating malignant solid tumors |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Fast-setting and / or cessation of substantially unchanged delivery of the product |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2678001B1 (fr) | 2011-02-25 | 2017-04-05 | South Dakota State University | Micelles de protéines conjuguées à un polymère |
WO2013020069A1 (fr) * | 2011-08-03 | 2013-02-07 | Ma Zhongmin | Traitement du diabète de type 2 avec du fty720 |
GB201304038D0 (en) * | 2013-03-06 | 2013-04-17 | Nhs Blood & Transplant | Treated cells and therapeutic uses |
BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20240042548A (ko) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
CA3012698A1 (fr) * | 2016-02-05 | 2017-08-10 | Entrega Inc. | Forme galenique orale comprenant un agent dessiccatif pour l'administration d'un agent actif |
MA53353A (fr) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (fr) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Administration continue d' exénatide et la co-adminstration d' acétaminophène, éthinylestradiol ou lévonorgestrel |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
CN113106054B (zh) * | 2020-01-13 | 2022-10-14 | 青岛瑞思德生物科技有限公司 | 一种将间充质干细胞诱导分化为胰岛细胞的诱导剂 |
CN111394311B (zh) * | 2020-04-20 | 2022-07-01 | 青岛瑞思德生物科技有限公司 | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3451974A (en) * | 1965-12-01 | 1969-06-24 | Du Pont | Process for moisture conditioning of nylon |
US3487139A (en) * | 1967-05-25 | 1969-12-30 | Mojonnier Inc Albert | Method of forming plastic articles |
US4289817A (en) * | 1970-09-14 | 1981-09-15 | Valyi Emery I | Decorated multilayered hollow plastic container |
US4421712A (en) * | 1980-08-13 | 1983-12-20 | Maryland Cup Corporation | Continuously rotary thermo-forming systems and apparatus of the pressure assist, plug assist and match mold type |
US4393373A (en) | 1981-03-16 | 1983-07-12 | Fuji Electrochemical Co., Ltd. | Piezoelectric audible sound generator |
JPS6028994A (ja) * | 1983-07-08 | 1985-02-14 | Wakunaga Seiyaku Kk | 〔21―ロイシン〕ヒトウロガストロン |
US4686283A (en) * | 1985-04-16 | 1987-08-11 | Syntex (U.S.A.) Inc. | Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis |
US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5554386A (en) | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
JPH04503154A (ja) | 1988-11-07 | 1992-06-11 | ルニベルシー・ド・ルタ・ア・リージュ | 変型ヒト成長ホルモン |
ATE114160T1 (de) * | 1989-01-24 | 1994-12-15 | Aphton Corp | Immunogenische zusammensetzungen gegen gastrin- peptide. |
US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
US5158935A (en) * | 1989-05-12 | 1992-10-27 | Chiron Corporation | Human epidermal growth factor having substitution at position 11 |
US5128242A (en) | 1989-06-19 | 1992-07-07 | The Administrators Of The Tulane Educational Fund | Hypothalamic polypeptides with adenylate cyclase stimulating activity |
US5198542A (en) | 1989-06-20 | 1993-03-30 | Takeda Chemical Industries, Inc. | Dna encoding a pitvitary adenylate cyclase activating protein and use thereof |
US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
EP0467279A3 (en) | 1990-07-18 | 1992-08-05 | Takeda Chemical Industries, Ltd. | Polypeptides having c-amp producing activity |
DE69231467T2 (de) * | 1991-05-10 | 2001-01-25 | Genentech Inc | Auswählen von agonisten und antagonisten von liganden |
WO1993003757A1 (fr) | 1991-08-16 | 1993-03-04 | Chiron Corporation | Muteines du facteur de croissance epidermique (fce) presentant une meilleure liaison a un ph faible |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
WO1994004330A1 (fr) * | 1992-08-11 | 1994-03-03 | E. Khashoggi Industries | Recipients a prise hydraulique |
US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
CA2121192A1 (fr) | 1993-04-21 | 1994-10-22 | Kiminori Atsumi | Membranes de collagene |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US6001647A (en) * | 1994-04-28 | 1999-12-14 | Ixion Biotechnology, Inc. | In vitro growth of functional islets of Langerhans and in vivo uses thereof |
WO1995029690A1 (fr) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Peptides biologiquement actifs et procedes permettant leur identification |
US5587309A (en) * | 1994-04-29 | 1996-12-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US20010006943A1 (en) * | 1994-12-23 | 2001-07-05 | Ejvind Jensen | Protracted GLP-1 compositions |
US6458764B1 (en) * | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
AU6163196A (en) | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
US6346390B1 (en) | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US6956026B2 (en) * | 1997-01-07 | 2005-10-18 | Amylin Pharmaceuticals, Inc. | Use of exendins for the reduction of food intake |
JP2001501593A (ja) * | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 胃腸運動を調節するための方法 |
US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1032388A4 (fr) | 1997-10-31 | 2002-10-02 | Smithkline Beecham Corp | Nouveaux complexes metalliques |
FR2770843B1 (fr) | 1997-11-13 | 2000-01-14 | Lavipharm Lab | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications |
EP1049486A4 (fr) * | 1997-12-05 | 2006-01-04 | Lilly Co Eli | Formulations de glp-1 |
WO1999043708A1 (fr) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derives de gpl-1 et de l'extendine au profil d'action etendu |
US20020127254A1 (en) | 1998-06-25 | 2002-09-12 | Lavipharm Laboratories Inc. | Devices for local and systemic delivery of active substance and methods of manufacturing thereof |
US6242563B1 (en) | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
AU5027299A (en) * | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
JP2002530064A (ja) | 1998-11-19 | 2002-09-17 | ミレニウム ファーマシューティカルズ,インコーポレーテッド | Egf様核酸およびポリペプチド、ならびにその使用 |
PT1143989E (pt) * | 1999-01-14 | 2007-03-30 | Amylin Pharmaceuticals Inc | Exendinas para supressão de glucagon |
JP4426727B2 (ja) * | 1999-01-14 | 2010-03-03 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 新規なエキセンジンアゴニスト製剤とその投与方法 |
US6451974B1 (en) * | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
IL149933A0 (en) * | 1999-12-06 | 2002-11-10 | Gen Hospital Corp | Pancreatic stem cells and their use in transplantation |
US6967100B2 (en) | 2000-02-18 | 2005-11-22 | The Walter And Eliza Hall Institute Of Medical Research | Pancreatic islet cell growth factors |
DK2055302T3 (da) * | 2000-03-31 | 2014-10-27 | Royalty Pharma Collection Trust | Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf |
US6992060B2 (en) | 2001-01-12 | 2006-01-31 | Waratah Pharmaceuticals, Inc. | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes |
CA2442177A1 (fr) * | 2001-03-29 | 2002-10-10 | Ixion Biotechnology, Inc. | Procede de transdifferentiation de cellules souches non pancreatiques dans la voie de differentiation du pancreas |
EP1401282A4 (fr) * | 2001-05-25 | 2005-03-30 | Cythera Inc | Differentiation de cellules souches |
EP1412384B1 (fr) * | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Formulation stable de glp-1 modifie |
US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
IL162131A0 (en) * | 2001-12-07 | 2005-11-20 | Geron Corp | Islet cells from human embryonic stem cells |
AU2003283004A1 (en) * | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
-
2003
- 2003-10-22 AU AU2003283004A patent/AU2003283004A1/en not_active Abandoned
- 2003-10-22 PL PL03376473A patent/PL376473A1/xx unknown
- 2003-10-22 US US10/532,295 patent/US20060189520A1/en not_active Abandoned
- 2003-10-22 EP EP08021849A patent/EP2080521A1/fr not_active Withdrawn
- 2003-10-22 EP EP03774936A patent/EP1569680B1/fr not_active Expired - Lifetime
- 2003-10-22 US US10/691,123 patent/US20040209801A1/en not_active Abandoned
- 2003-10-22 DE DE60326002T patent/DE60326002D1/de not_active Expired - Lifetime
- 2003-10-22 ES ES03774936T patent/ES2320754T3/es not_active Expired - Lifetime
- 2003-10-22 MX MXPA05004202A patent/MXPA05004202A/es active IP Right Grant
- 2003-10-22 JP JP2004547077A patent/JP2006506386A/ja active Pending
- 2003-10-22 KR KR1020057006825A patent/KR20050074492A/ko not_active Application Discontinuation
- 2003-10-22 DK DK03774936T patent/DK1569680T3/da active
- 2003-10-22 CA CA002501677A patent/CA2501677A1/fr not_active Abandoned
- 2003-10-22 AT AT03774936T patent/ATE421333T1/de active
- 2003-10-22 BR BR0315523-4A patent/BR0315523A/pt not_active Application Discontinuation
- 2003-10-22 WO PCT/US2003/033595 patent/WO2004037195A2/fr active Application Filing
-
2005
- 2005-05-19 NO NO20052419A patent/NO20052419L/no not_active Application Discontinuation
-
2008
- 2008-10-16 US US12/252,814 patent/US20090036381A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL376473A1 (en) | 2005-12-27 |
ATE421333T1 (de) | 2009-02-15 |
ES2320754T3 (es) | 2009-05-28 |
NO20052419L (no) | 2005-07-07 |
US20090036381A1 (en) | 2009-02-05 |
JP2006506386A (ja) | 2006-02-23 |
EP1569680A4 (fr) | 2006-05-17 |
AU2003283004A1 (en) | 2004-05-13 |
MXPA05004202A (es) | 2005-09-20 |
WO2004037195A3 (fr) | 2005-06-16 |
KR20050074492A (ko) | 2005-07-18 |
EP1569680B1 (fr) | 2009-01-21 |
NO20052419D0 (no) | 2005-05-19 |
EP2080521A1 (fr) | 2009-07-22 |
CA2501677A1 (fr) | 2004-05-06 |
BR0315523A (pt) | 2005-08-30 |
EP1569680A2 (fr) | 2005-09-07 |
DE60326002D1 (de) | 2009-03-12 |
WO2004037195A2 (fr) | 2004-05-06 |
US20040209801A1 (en) | 2004-10-21 |
US20060189520A1 (en) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1569680T3 (da) | Behandling af diabetes | |
CY1119865T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον | |
DE60329724D1 (de) | Methoden und Kompositionen um Diabetes zu behandeln | |
ECSP067095A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
DK1734971T3 (da) | Indretning på polymerbasis med forsinket frigivelse | |
ATE412387T1 (de) | Medizinische vorrichtungen | |
BR0207871A (pt) | Composição para liberar bisfosfonato para um alvo | |
AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
NO20065368L (no) | Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin | |
NO20071914L (no) | Kontrollert avleveringssystem | |
DK2026803T3 (da) | Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf | |
GT200500119A (es) | Derivados de tetraazabenzo [e] azuleno y sus analogos | |
BR0314356A (pt) | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas | |
DK1749517T3 (da) | Stabil farmaceutiske sammensætning af linezolid form IV | |
DK1185253T3 (da) | Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac | |
ECSP044981A (es) | Composicion oftalmica que comprende ascomicina | |
CY1114480T1 (el) | Συνθεσεις που περιλαμβανουν διαχωρισμενο αγωνιστη υποδοχεα γλυκοκορτικοειδους για τη θεραπεια ή τον ελεγχο φλεγμονης προσθιου τμηματος | |
BRPI0500536A (pt) | Composição antimicrobiana | |
PA8584501A1 (es) | Nuevos derivados de oxazol | |
ATE404156T1 (de) | Ein matrizenband | |
DK1603584T3 (da) | Aplidine til behandling af multipelt myelom | |
NO20091691L (no) | Pegylert PTH som PTH-reseptormodulatorer og anvendelse derav | |
RS52038B (en) | USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS | |
SE0402636D0 (sv) | Chemical compounds |